TY - JOUR
T1 - Portuguese Heart Failure Prevalence Observational Study (PORTHOS) rationale and design – a population-based study
AU - Baptista, Rui
AU - Silva Cardoso, José
AU - Canhão, Helena
AU - Maria Rodrigues, Ana
AU - Kislaya, Irina
AU - Franco, Fátima
AU - Bernardo, Filipa
AU - Pimenta, Joana
AU - Mendes, Lígia
AU - Gonçalves, Sara
AU - Teresa Timóteo, Ana
AU - Andrade, Aurora
AU - Moura, Brenda
AU - Fonseca, Cândida
AU - Aguiar, Carlos
AU - Brito, Dulce
AU - Ferreira, Jorge
AU - Filipe Azevedo, Luís
AU - Peres, Marisa
AU - Santos, Paulo
AU - Moraes Sarmento, Pedro
AU - Cernadas, Rui
AU - Santos, Mário
AU - Fontes-Carvalho, Ricardo
AU - Campos Fernandes, Adalberto
AU - Martinho, Hugo
AU - González-Juanatey, José Ramon
AU - Filipe Pereira, Luís
AU - Gil, Victor
AU - Raquel Marques, Cláudia
AU - Almeida, Mário
AU - Pardal, Marisa
AU - Barbosa, Veneranda
AU - Gavina, Cristina
N1 - Publisher Copyright:
© 2023 Sociedade Portuguesa de Cardiologia
PY - 2023/12
Y1 - 2023/12
N2 - Introduction and objectives: Current epidemiological data on heart failure (HF) in Portugal derives from studies conducted two decades ago. The main aim of this study is to determine HF prevalence in the Portuguese population. Using current standards, this manuscript aims to describe the methodology and research protocol applied. Methods: The Portuguese Heart Failure Prevalence Observational Study (PORTHOS) is a large, three-stage, population-based, nationwide, cross-sectional study. Community-dwelling citizens aged 50 years and older will be randomly selected via stratified multistage sampling. Eligible participants will be invited to attend a screening visit at a mobile clinic for HF symptom assessment, anthropomorphic assessment, N-terminal pro-B-type natriuretic peptide (NT-proBNP) testing, one-lead electrocardiogram (ECG) and a sociodemographic and health-related quality of life questionnaire (EQ-5D). All subjects with NT-proBNP ≥125 pg/mL or with a prior history of HF will undergo a diagnostic confirmatory assessment at the mobile clinic composed of a 12-lead ECG, comprehensive echocardiography, HF questionnaire (KCCQ) and blood sampling. To validate the screening procedure, a control group will undergo the same diagnostic assessment. Echocardiography results will be centrally validated, and HF diagnosis will be established according to the European Society of Cardiology HF guidelines. A random subsample of patients with an equivocal HF with preserved ejection fraction diagnosis based on the application of the Heart Failure Association preserved ejection fraction diagnostic algorithm will be invited to undergo an exercise echocardiography. Conclusions: Through the application of current standards, appropriate methodologies, and a strong research protocol, the PORTHOS study will determine the prevalence of HF in mainland Portugal and enable a comprehensive characterization of HF patients, leading to a better understanding of their clinical profile and health-related quality of life.
AB - Introduction and objectives: Current epidemiological data on heart failure (HF) in Portugal derives from studies conducted two decades ago. The main aim of this study is to determine HF prevalence in the Portuguese population. Using current standards, this manuscript aims to describe the methodology and research protocol applied. Methods: The Portuguese Heart Failure Prevalence Observational Study (PORTHOS) is a large, three-stage, population-based, nationwide, cross-sectional study. Community-dwelling citizens aged 50 years and older will be randomly selected via stratified multistage sampling. Eligible participants will be invited to attend a screening visit at a mobile clinic for HF symptom assessment, anthropomorphic assessment, N-terminal pro-B-type natriuretic peptide (NT-proBNP) testing, one-lead electrocardiogram (ECG) and a sociodemographic and health-related quality of life questionnaire (EQ-5D). All subjects with NT-proBNP ≥125 pg/mL or with a prior history of HF will undergo a diagnostic confirmatory assessment at the mobile clinic composed of a 12-lead ECG, comprehensive echocardiography, HF questionnaire (KCCQ) and blood sampling. To validate the screening procedure, a control group will undergo the same diagnostic assessment. Echocardiography results will be centrally validated, and HF diagnosis will be established according to the European Society of Cardiology HF guidelines. A random subsample of patients with an equivocal HF with preserved ejection fraction diagnosis based on the application of the Heart Failure Association preserved ejection fraction diagnostic algorithm will be invited to undergo an exercise echocardiography. Conclusions: Through the application of current standards, appropriate methodologies, and a strong research protocol, the PORTHOS study will determine the prevalence of HF in mainland Portugal and enable a comprehensive characterization of HF patients, leading to a better understanding of their clinical profile and health-related quality of life.
KW - Heart failure
KW - Prevalence
KW - Quality of life
KW - Portugal
KW - Epidemiology
KW - PORTHOS
KW - Insuficiência cardíaca
KW - Prevalência
KW - Qualidade de vida
KW - Portugal
KW - Epidemiologia
KW - PORTHOS
UR - http://www.scopus.com/inward/record.url?scp=85178151110&partnerID=8YFLogxK
U2 - 10.1016/j.repc.2023.10.004
DO - 10.1016/j.repc.2023.10.004
M3 - Article
C2 - 37918783
AN - SCOPUS:85178151110
SN - 0870-2551
VL - 42
SP - 985
EP - 995
JO - Revista Portuguesa de Cardiologia
JF - Revista Portuguesa de Cardiologia
IS - 12
ER -